Bactolife gets €30M to commercialise its proprietary Binding Proteins technology
August 8, 2023
Proceeds from the financing will enable Bactolife to advance its most mature projects towards commercial launch and strengthen the technology platform and upscaling capabilities. By doing so, the company aims at retaining its first mover advantage to transform human and animal health with target specific Binding Proteins.
Funding 💰
Round €30M
Series A
Series A
Lead investor(s) ATHOS
Also participating Bill & Melinda Gates Foundation, Novo Holdings
Quotes 💬
“
We are very pleased and humbled by the continued confidence that investors have shown us, especially in times of geopolitical uncertainty and market turmoil. The funding allows us to increase our investments in our project pipeline, technology platform, organisation and upscaling capabilities. Further, it will enable Bactolife to accelerate our partnering efforts with world-leading companies and commercialise our first product concepts for humans and animals.
— Sebastian Søderberg, CEO of Bactolife
“
Infectious diseases and increasing antimicrobial resistance are amongst the biggest threats to global health and development. We are committed to addressing this challenge and believe in Bactolife's targeted solutions.
— Julian Zachmann, Investment Manager at ATHOS
“
The successful Series A is another validation of Bactolife's impressive achievements and opportunity for the future. Bactolife is a great example of the strong Danish biotech ecosystem, as its technology platform originates from a Danish University, and was then further enabled by pioneering Danish biotech companies and talents. This bodes well for the future of not only Bactolife, but the Danish biotech sector as a whole. Further, I am very pleased that the international investors share our enthusiasm for finding solutions to the global AMR crisis. Combatting antimicrobial resistance requires all hands on deck.
— Aleks Engel, Partner at Novo Holdings
About 🏢
Bactolife uses its proprietary Binding Protein technology to develop novel biological solutions, strengthening the gut microbiome and helping solve the daunting challenge of antimicrobial resistance (AMR) development, as well as the general burden of infectious diseases. Its proprietary platform consists of a technology for selecting and producing Binding Proteins that acts on toxins without targeting growth or killing the bacteria directly. The company is developing and will market ingredients for Mothers & Children, Elderly, Immunodeficient, Travelers & Deployed and Animal Health. The company has proof of concept (PoC) of its technology among others from testing its most advanced animal health product, Ablacto+ that stabilizes the gut of piglets and reduce the severity of post weaning diarrhea (PWD), in more than 6,000 piglets. more
Latest @ 
Bactolife gets €30M to commercialise its proprietary Binding Proteins technology
KetoSwiss raises $4.8M in 2nd closing of its pre-series A round
Luxembourg's accelerator Fit 4 Start #14 is now open
CathVision secures $9M for its ECGenius System and CARDIALYTICS AI-Suite
Germany's biotech firm AATec Medical raises €2.7M in Seed financing